Deshpande博士为首席战略官兼美国运营负责人 和铂医药任命Atul

作者:和铂医药 / 公众号:Harbour_BioMed 发布时间:2019-01-05


和铂医药任命Atul Deshpande博士为首席战略官兼美国运营负责人
并任命陈小祥医师为首席产品开发官、廖迈菁博士为首席商务官
Harbour BioMed Appoints Atul Deshpande, Ph.D MBA, Chief Strategy Officerand Head of U.S. Operations;
Promotes Xiaoxiang Chen, MD to Chief Development Officer, and Mai-Jing Liao, Ph.D., MBA to Chief Business Officer
(*Please scroll down for English version)
中国上海,荷兰鹿特丹,美国马塞诸塞州剑桥
2019年1月4日
和铂医药今日宣布,任命Atul Deshpande博士为首席战略官,并兼任美国运营负责人。Deshpande博士此前在赛诺菲健赞担任Dupixent® (dupilumab)部门全球运营负责人。

Dr. Atul Deshpande
“Deshpande博士在免疫及多个疾病领域拥有丰富的行业经验,并且在医药行业的整个价值链上,从战略到业务执行均有丰富经验。” 和铂医药创始人,董事长兼首席执行官王劲松博士表示,“和铂医药成立两年以来,迅速拓展了其药物开发技术平台并建立了核心研发产品管线。Deshpande博士加入后,将从战略制定与推进等角度促进和铂医药下一阶段的成长,同时他将负责公司在美国的业务运营。”
Deshpande博士此前在赛诺菲健赞任职期间,从战略到项目运营层面,成功地承担了越来越重大的责任。他负责了重磅药物Dupixent® (dupilumab)针对特应性皮炎以及哮喘这两大适应症全球上市工作的整体运营与执行。此外,Deshpande博士拥有非常丰富的全球工作经验,他曾负责制定赛诺菲亚太地区的研发战略,对中国和日本的医药研发市场有非常深刻的了解。在加入赛诺菲之前,Deshpande博士曾在几家专注生命科学领域的战略咨询公司工作。
Deshpande博士在加利福尼亚大学尔湾分校获神经生物与行为学博士学位,并在英国克兰菲尔德大学获得MBA学位。
和铂医药宣布任命陈小祥医师为首席产品开发官、廖迈菁博士为首席商务官
和铂医药同时宣布,任命陈小祥医师为首席产品开发官,廖迈菁博士为首席商务官。
关于和铂
和铂医药是一家全球化的生物制药公司,利用其拥有全球专利的两个全人源抗体转基因小鼠平台研发针对肿瘤和免疫性疾病的创新疗法。和铂医药还通过与业务伙伴的多元化合作快速拓展其新药研发管线。同时,和铂医药通过其全资子公司Harbour Antibodies向全球生物制药公司和学术机构授权其专利技术平台用于多种抗体新药研发。更多信息请见http://www.harbourbiomed.com
联系方式
王悦,和铂医药,中国上海
+86-138-1854-2349
yue.wang@harbourbiomed.com
Timothy Miller, Harbour Antibodies US, Boston
+1-857-214-0976
timothy.miller@harbourbiomed.com
Harbour BioMed Appoints Atul Deshpande, Ph.D MBA, Chief Strategy Officer
and Head of U.S. Operations
CAMBRIDGE, Mass, SHANGHAI, China & ROTTERDAM, The Netherlands.
January 4th, 2019
Harbour BioMed announced the appointment of Atul Deshpande, PhD MBA, as Chief Strategy Officer and Head of U.S. Operations. Dr. Deshpande joins Harbour BioMed from Sanofi, where he served as Global Operations Lead of Sanofi Genzyme’s Dupixent® (dupilumab) franchise.
“Atul brings a wealth of industry experience in immunology and other therapeutic areas and across the pharmaceutical value chain, including both strategy and execution,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “Harbour BioMed has rapidly expanded its drug discovery platforms and built an initial R&D portfolio since it was founded two years ago. Atul will be integral to developing and driving corporate strategy for the next stage of our growth. He will also oversee our U.S. business operations.”
During his tenure at Sanofi Genzyme, Dr. Deshpande delivered on roles with increasing responsibility from strategy to implementation. He was instrumental in establishing and executing global Dupixent launches in Atopic Dermatitis and Asthma, a blockbuster brand in the making. He also brings significant international experience, having developed the R&D strategy for the company’s Asia Pacific businesses, including Japan and China. Prior to Sanofi Genzyme, Dr. Deshpande served at several life science strategic consulting firms.
Dr. Deshpande holds a Ph.D. in Neurobiology and Behavior from University of California, Irvine and an MBA from Cranfield University in the UK.
The company also names Chief Development, Chief Business Officers
Harbour BioMed also announced the promotions of Dr. Xiaoxiang Chen, MD to Chief Development Officer, and Dr. Mai-Jing Liao, Ph.D., MBA to Chief Business Officer, effective immediately.
About Harbour Biomed
Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. The company's discovery and development programs are built around its two patented transgenic mouse platforms for therapeutic antibody discovery. The company is building a proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For more information, visit www.harbourbiomed.com.
Contacts
Timothy Miller, Harbour Antibodies US, Boston
+1-857-214-0976
timothy.miller@harbourbiomed.com
Yue Wang, Harbour BioMed, Shanghai
+86-138-1854-2349
yue.wang@harbourbiomed.com

和铂新闻
官宣!临床试验默示许可正式落地 和铂医药项目入选首批名单
和铂医药授权百济神州使用其全人源抗体平台开发多种抗体新药
和铂医药与科伦博泰开展全球合作,共同开发多个创新全人源抗体药物
和铂医药宣布,已授权信达生物使用其抗体平台技术开发全人源单克隆抗体新药
和铂医药完成B轮融资8500万美元 加速创新产品线研发

关注和铂医药微信公众号,获取更多图文精彩内容


其他栏目